Skip to main content

Table 3 Characteristics of LT recipients by period: 2001–2010 and 2011–2019

From: Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease

 

2001–2010

2011–2019

p value

N transplants

265

744

 

LT etiology*†

NASH

27 (10.2%)

221 (29.7%)

 < 0.001

HCV

111 (41.9%)

176 (23.7%)

HBV

56 (21.1%)

168 (22.6%)

Wilson's disease

11 (4.2%)

12 (1.6%)

PSC

4 (1.5%)

24 (3.2%)

AIH

29 (10.9%)

60 (8.1%)

SCH

5 (1.9%)

16 (2.2%)

Other

22 (8.3%)

67 (9.0%)

Age [Median (IQR)]*‡

50 (37–57)

56 (47–63)

 < 0.001

Male†

166 (62.6%)

468 (62.9%)

0.940

BMI [Median (IQR)]‡

26.0 (22.4–30.0)

26.2 (22.9–30.6)

0.299

BMI group [n (%)]†

Underweight

13 (4.9%)

36 (4.8%)

0.767

Normal weight

97 (36.6%)

269 (36.2%)

Pre-obesity

81 (30.6%)

227 (30.5%)

Obesity (class 1)

47 (17.7%)

147 (19.8%)

Obesity (class 2)

15 (5.7%)

45 (6.1%)

Obesity (class 3)

12 (4.5%)

20 (2.7%)

Waitlist time [Median days (IQR)]*‡

82 (21–206)

43 (15–112)

 < 0.001

LT from living donor [n (%)]*†

74 (27.9%)

554 (74.5%)

 < 0.001

MELD score [Median (IQR)]*‡

19 (14–28)

22 (17–25)

0.001

HCC candidate [n (%)]*†

57 (21.5%)

225 (30.2%)

0.007

  1. LT, liver transplant; NASH, nonalcoholic steatohepatitis; HCV, hepatitis C virus; HBV, hepatitis B virus; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; SCH, schistosomiasis; BMI, body mass index; MELD, model for end-stage liver disease; HCC, hepatocellular carcinoma
  2. *Significant difference between 2001–2010 and 2011–2019
  3. †Periods compared with χ2 test
  4. ‡Periods compared with Kruskal–Wallis equality of populations rank test